Articles tagged with: Revlimid
Remember Love Canal?
If you came of age in the 1970s or earlier in the United States, you surely remember Love Canal.
Love Canal was a neighborhood in Niagara Falls, New York, built atop a chemical waste dump that had been closed and covered with dirt in the early 1950s. An elementary school was built first, followed soon by the houses.
Even though residents soon started noticing odd smells and oily substances leaching up into the playground, it wasn’t until 1976 that the dump, after unusually heavy rains and …
Findings from a prospective Phase 2 clinical trial indicate that the combination of Revlimid, Velcade, and dexamethasone is effective in relapsed and refractory multiple myeloma patients.
The trial enrolled 64 patients, who had been treated with a median of two prior therapies, at six different U.S. cancer centers from 2006 to 2008.
Nearly two-thirds of the patients in the trial achieved at least a partial response, despite the fact that more than half of the patients had previously been treated with Velcade (bortezomib), and nearly three quarters had …
The findings of a recent retrospective study may alleviate some of the concerns patients and physicians have had about Revlimid and the risk of secondary cancers.
The study found that the risk of developing a secondary cancer as a result of treatment with Revlimid occurred mainly when a patient had been treated with oral melphalan at the same time as Revlimid.
In addition, although treatment with …
One of the issues that a physician may consider when deciding how to treat a myeloma patient is the impact different treatment options may have on the patient’s bones.
If a patient already has extensive bone damage resulting from multiple myeloma, a physician may lean more toward treatments that are believed to halt, or even counteract, the bone destruction the patient has been experiencing.
However, there …
The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.
Previous years have witnessed research shedding new light on existing myeloma therapies, as well as additional research about potential new therapies.
But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic improvements in the treatment of the disease.
In 2013, not only was there more research about existing therapies, and more …